ST317 / STipe Therap - LARVOL DELTA

ST317. Understanding and Mitigating Perioperative Deteriorations: Unanticipated ICU Admission, Boarding and Adverse Events in PACU. (1 PS, 1 CME) (ASA 2025) - "From attending this session, participants will gain familiarity with the relevant literature and a clear understanding of how to implement those approaches in their clinical practice. SessionLearningObjective1: Analyze causes of unanticipated ICU admission and their relationship with the quality of anesthesia care.SessionLearningObjective2: Recognize the multiple demands and conflicting priorities of providing care to PACU patients.SessionLearningObjective3: Appraise optimum communication strategies and develop algorithms for safe patient care in the PACU."

Adverse events • CME • Anesthesia

ST317. Emerging Blood Management Strategies for Intracranial Surgery: The Products, the Pharma, and POC Testing (ASA 2024) - "Learning Objective 2 Choose pharmacologic adjuvants to address coagulopathy and bleeding for intracranial surgical patients including antifibrinolytics and factor concentrates. Learning Objective 3 Describe how to use POC testing to guide transfusion in patients undergoing craniotomy"

Surgery • Anemia • Hematological Disorders • Obstetrics

ST317. How to Safely Manage Atypical Clinical Situations: Tips from the Anesthesia Patient Safety Editorial Board (ASA 2023) - "DESCRIPTION This session will address safety issues related to situations that are not quite the norm, such as in NORA locations, in crisis situations, mass casualty situations or when colleagues are in danger. These discussions address expanding environments of care and other situations outside the comfort zone of our normal operating room business."

Clinical • Anesthesia

Systemic delivery of ST317, a cell penetrating STING pathway sensitizer, results in strong anti-tumor activity (AACR 2023) - "In vitro, ST317 sensitizes STING to pathway activators (Cytoplasmic DNA and cGAMP) and pharmacological STING agonists including ADU-S100 and diABZI compound 3, reducing the EC50 values of agonist-induced STING pathway activation while inducing supraphysiological (i.e. increasing the EMax) levels of pro-inflammatory cytokines/chemokines (e.g. Type I interferon and CXCL10) in cell line and primary cells. Jønsson et al. 2017 DOI: 10.1038/ncomms14391"

Oncology • CXCL10 • IFI16